loading
전일 마감가:
$36.96
열려 있는:
$36.2
하루 거래량:
5.63M
Relative Volume:
1.19
시가총액:
$74.78B
수익:
$40.10B
순이익/손실:
$3.26B
주가수익비율:
23.14
EPS:
1.5831
순현금흐름:
$4.57B
1주 성능:
+1.30%
1개월 성능:
+8.47%
6개월 성능:
-12.45%
1년 성능:
-12.64%
1일 변동 폭
Value
$36.05
$36.67
1주일 범위
Value
$36.05
$37.22
52주 변동 폭
Value
$31.71
$45.92

글락소스미스클라인 ADR Stock (GSK) Company Profile

Name
명칭
Gsk Plc Adr
Name
전화
-
Name
주소
-
Name
직원
70,200
Name
트위터
@GSK
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
GSK's Discussions on Twitter

GSK을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
GSK
Gsk Plc Adr
36.64 74.78B 40.10B 3.26B 4.57B 1.5831
Drug Manufacturers - General icon
LLY
Lilly Eli Co
873.68 830.35B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
88.08 390.99B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
ABBV
Abbvie Inc
202.08 356.74B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
JNJ
Johnson Johnson
162.30 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
MRK
Merck Co Inc
89.50 251.88B 64.17B 17.12B 14.84B 6.7297

글락소스미스클라인 ADR Stock (GSK) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-12 개시 Morgan Stanley Equal-Weight
2024-11-15 다운그레이드 Deutsche Bank Buy → Hold
2024-11-12 다운그레이드 Jefferies Buy → Hold
2024-10-31 다운그레이드 Guggenheim Buy → Neutral
2024-07-08 다운그레이드 UBS Buy → Neutral
2024-05-30 개시 Goldman Neutral
2024-03-04 업그레이드 Guggenheim Neutral → Buy
2024-02-13 업그레이드 Citigroup Neutral → Buy
2024-01-23 개시 Morgan Stanley Equal-Weight
2024-01-16 재개 UBS Buy
2024-01-03 업그레이드 Jefferies Hold → Buy
2023-07-14 개시 HSBC Securities Reduce
2023-03-17 업그레이드 Deutsche Bank Hold → Buy
2023-02-27 재개 Goldman Buy
2023-01-03 다운그레이드 JP Morgan Neutral → Underweight
2022-12-05 다운그레이드 BofA Securities Neutral → Underperform
2022-11-11 다운그레이드 UBS Neutral → Sell
2022-09-15 업그레이드 Credit Suisse Underperform → Neutral
2022-09-08 다운그레이드 Jefferies Buy → Hold
2022-08-05 재개 Morgan Stanley Equal-Weight
2022-07-21 재개 Citigroup Neutral
2022-02-11 다운그레이드 DZ Bank Buy → Hold
2021-11-05 업그레이드 Barclays Underweight → Equal Weight
2021-06-24 업그레이드 Deutsche Bank Sell → Hold
2021-03-23 다운그레이드 SVB Leerink Outperform → Mkt Perform
2021-02-04 다운그레이드 Deutsche Bank Hold → Sell
2021-01-20 다운그레이드 Credit Suisse Neutral → Underperform
2021-01-15 개시 Deutsche Bank Hold
2020-11-02 업그레이드 Liberum Hold → Buy
2020-09-29 개시 Berenberg Buy
2020-02-12 다운그레이드 Shore Capital Hold → Sell
2020-01-16 다운그레이드 Barclays Equal Weight → Underweight
2019-12-02 개시 SVB Leerink Outperform
2019-11-21 업그레이드 UBS Neutral → Buy
2019-10-11 업그레이드 Cantor Fitzgerald Hold → Buy
2019-09-03 재개 Citigroup Neutral
2019-09-03 업그레이드 Societe Generale Sell → Buy
2019-08-13 재개 JP Morgan Neutral
2019-06-17 재개 Morgan Stanley Underweight
2019-03-08 다운그레이드 Shore Capital Buy → Hold
2019-02-22 다운그레이드 UBS Buy → Neutral
2019-01-14 다운그레이드 Exane BNP Paribas Outperform → Neutral
2018-12-11 재개 Jefferies Buy
2018-10-09 개시 Guggenheim Neutral
2018-08-30 다운그레이드 Liberum Buy → Hold
2018-04-04 업그레이드 Exane BNP Paribas Neutral → Outperform
2018-03-22 업그레이드 Morgan Stanley Underweight → Equal-Weight
2018-02-09 업그레이드 Kepler Reduce → Hold
모두보기

글락소스미스클라인 ADR 주식(GSK)의 최신 뉴스

pulisher
Feb 21, 2025

April 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against GSK - GlobeNewswire Inc.

Feb 21, 2025
pulisher
Feb 21, 2025

Deadline Alert: GSK plc. (GSK) Investors Who Lost Money - GlobeNewswire

Feb 21, 2025
pulisher
Feb 21, 2025

Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - TradingView

Feb 21, 2025
pulisher
Feb 14, 2025

A closer look at Gold Fields Ltd ADR’s (GFI) current quarter earnings projections - US Post News

Feb 14, 2025
pulisher
Feb 11, 2025

Law Offices of Frank R. Cruz Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire

Feb 11, 2025
pulisher
Feb 10, 2025

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire

Feb 10, 2025
pulisher
Feb 07, 2025

Is GSK Plc ADR (GSK) worth investing in despite its undervalued state? - US Post News

Feb 07, 2025
pulisher
Feb 07, 2025

Chewy Inc (CHWY) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News

Feb 07, 2025
pulisher
Feb 06, 2025

GSK PLC Stockholder Notice: Shareholder Rights Law Firm - GlobeNewswire

Feb 06, 2025
pulisher
Feb 06, 2025

O’Reilly Automotive, Inc [ORLY] stock for 2,179,380 USD was sold by CONN TAMARA F. - Knox Daily

Feb 06, 2025
pulisher
Feb 06, 2025

Buying Buzz: GSK Plc ADR [GSK] 10% Owner GSK plc purchases 2,791,930 shares of the company - Knox Daily

Feb 06, 2025
pulisher
Feb 06, 2025

Bear Of The Day: GSK PLC (GSK) - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

MNKD Shares Experience Surge in Value - Knox Daily

Feb 06, 2025
pulisher
Feb 06, 2025

Torrid Holdings Inc [CURV] Shares Jump Approximately 29.38% Over the Year - Knox Daily

Feb 06, 2025
pulisher
Feb 06, 2025

D-Wave Quantum Inc [QBTS] Records 200-Day SMA of $2.33 - Knox Daily

Feb 06, 2025
pulisher
Feb 06, 2025

Rumble Inc [RUM] Records 50-Day SMA of $10.53 - Knox Daily

Feb 06, 2025
pulisher
Feb 05, 2025

Investor Alert: Robbins LLP Informs Stockholders of the GSK PLC Class Action - PR Newswire

Feb 05, 2025
pulisher
Feb 05, 2025

Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Large Losses to Contact the Firm for Information About Their Rights - Business Wire

Feb 05, 2025
pulisher
Feb 05, 2025

Wall Street Analyst Downgrade Melco Resorts & Entertainment Ltd ADR [MLCO]. What else is Wall St. saying - The DBT News

Feb 05, 2025
pulisher
Feb 05, 2025

GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook - Yahoo Finance

Feb 05, 2025
pulisher
Feb 05, 2025

For Juniper Networks Inc [JNPR], Analyst sees a rise to $40. What next? - The DBT News

Feb 05, 2025
pulisher
Feb 05, 2025

Market Analysts see Apollo Global Management Inc [APO] gaining to $188. Time to buy? - The DBT News

Feb 05, 2025
pulisher
Feb 05, 2025

Tuya Inc ADR [TUYA] Revenue clocked in at $280.97 million, up 66.48% YTD: What’s Next? - The DBT News

Feb 05, 2025
pulisher
Feb 04, 2025

GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Feb 04, 2025
pulisher
Feb 04, 2025

The Significance of Moving Averages in BridgeBio Pharma Inc Inc. (BBIO) Price Performance - The InvestChronicle

Feb 04, 2025
pulisher
Feb 03, 2025

Top investors say GSK Plc ADR (GSK) ticks everything they need - SETE News

Feb 03, 2025
pulisher
Jan 31, 2025

GSK share price - GSK

Jan 31, 2025
pulisher
Jan 29, 2025

Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline - Yahoo Finance

Jan 29, 2025
pulisher
Jan 28, 2025

Are Investors Keen On Selling Holdings In GSK Plc ADR (NYSE: GSK)? - Stocks Register

Jan 28, 2025
pulisher
Jan 28, 2025

Dow Inc (NYSE: DOW) Is A Buzzing Hot Stock - Stocks Register

Jan 28, 2025
pulisher
Jan 27, 2025

The 10 Best Companies to Invest in Now - Morningstar

Jan 27, 2025
pulisher
Jan 23, 2025

In 2025, GSK Plc ADR (NYSE: GSK) Shares Will Likely Be Bullish - Stocks Register

Jan 23, 2025
pulisher
Jan 14, 2025

18 of the Best Stocks and ETFs to Buy Based on 2025 Expert Forecasts - Morningstar

Jan 14, 2025
pulisher
Jan 07, 2025

Precidian Investments Builds Out Its ADRhedged ETF Lineup with Four New Strategies, Offering Targeted International Exposure with Integrated Currency Hedge - Business Wire

Jan 07, 2025
pulisher
Dec 23, 2024

Gsk Plc ADR (GSK-N) QuotePress Release - The Globe and Mail

Dec 23, 2024
pulisher
Dec 16, 2024

Best International Companies to Own: 2025 Edition - Morningstar

Dec 16, 2024
pulisher
Dec 12, 2024

FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - MSN

Dec 12, 2024
pulisher
Dec 11, 2024

GSK Stock Declines 20% In 3 Months: Should You Buy, Sell Or Hold? - Barchart

Dec 11, 2024
pulisher
Dec 11, 2024

GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold? - Zacks Investment Research

Dec 11, 2024
pulisher
Dec 09, 2024

FDA Accepts GSK's Filing For Expanded Use Of Nucala In COPD - Barchart

Dec 09, 2024

글락소스미스클라인 ADR (GSK) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general SNY
$54.46
price up icon 0.61%
$109.95
price down icon 0.07%
drug_manufacturers_general PFE
$26.30
price up icon 1.54%
$303.01
price up icon 1.71%
drug_manufacturers_general NVS
$109.35
price up icon 1.90%
drug_manufacturers_general MRK
$89.50
price up icon 2.08%
자본화:     |  볼륨(24시간):